Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alintegimod - 7 Hills Pharma

Next Previous
Drug Profile

Alintegimod - 7 Hills Pharma

Alternative Names: 7HP-349; Alintegimod

Latest Information Update: 23 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 7 Hills Pharma
  • Developer 7 Hills Pharma; University of Texas Health Science Center at Houston
  • Class Adjuvants; Antineoplastics; Antiprotozoals; Antituberculars; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Integrin alpha4beta1 agonists; Lymphocyte function-associated antigen-1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Chagas disease; COVID 2019 infections; Influenza virus infections; Solid tumours; Tuberculosis

Most Recent Events

  • 23 Dec 2024 Chemical structure information added.
  • 03 Sep 2024 Pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers released by 7 Hills Pharma
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Chagas-disease(Prevention) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top